drugset / Trial / NCT01493427

Efficacy of Changing to TRAVATAN® From Prior Therapy

NCT01493427

Phase 4 Completed 202 enrolled Alcon Research
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study was to assess the efficacy and tolerability of TRAVATAN® Solution without benzalkonium chloride (BAK) in patients previously on latanoprost 0.005% or bimatoprost 0.01% ophthalmic solution monotherapy.

Timeline

Start
2011-12
Primary completion
2013-02
Completion
2013-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Travoprost Other / unclassified 0.004 % Other